Imaging 26S proteasome activity and inhibition in living mice

Nature Medicine

Volumn 9, Issue 7, 2003, Pages 969-973

  Luker, Gary D ^a   Pica, Christina M ^a   Song, Jiling ^a   Luker, Kathryn E ^a   Piwnica Worms, David ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; LUCIFERASE; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CARCINOGENESIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOSE RESPONSE; GENETIC TRANSFECTION; HELA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REPORTER GENE; STEADY STATE; WESTERN BLOTTING;

ACETYLCYSTEINE; ANIMALS; BEETLES; BORONIC ACIDS; CYSTEINE PROTEINASE INHIBITORS; GENES, REPORTER; HELA CELLS; HUMANS; KINETICS; LEUPEPTINS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, NUDE; MOLECULAR BIOLOGY; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TRANSFECTION; UBIQUITIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 0038378519     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm894     Document Type: Article

References (22)

1. Sakamoto, K. Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. Mol. Genet. Metab. 77, 44-56 (2002).
2. Glickman, M. & Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428 (2002).
3. Pye, J. et al. Proteasome inhibition ablates activation of NF-κB induced during myocardial reperfusion and reduces reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 284, H919-H926 (2002).
4. Zhang, L. et al. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32, 2926-2931 (2001).
5. Adams, J. Proteasome inhibitors as new anticancer drugs. Curr. Opin. Oncol. 14, 628-634 (2002).
6. Hideshima, T. & Anderson, K. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer 2, 927-937 (2002).
7. Voges, D., Zwickl, P. & Baumeister, W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015-1068 (1999).
8. Navon, A. & Goldberg, A. Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. Mol. Cell 8, 1339-1349 (2001).
9. Leggett, D. et al. Multiple associated proteins regulate proteasome structure and function. Mol. Cell 10, 495-507 (2002).
10. Lightcap, E. et al. Proteasome inhibition measurements: clinical application. Clin. Chem. 46, 673-683 (2000).
11. Stack, J., Whitney, M., Rodems, S. & Pollok, B. A ubiquitin-based tagging system for controlled modulation of protein stability. Nat. Biotechnol. 18, 1298-1302 (2000).
12. Kang, Z., Pirskanen, A., Janne, O. & Palvimo, J. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J. Biol. Chem. 277, 48366-48371 (2002).
13. Deroo, B. & Archer, T. Proteasome inhibitors reduce luciferase and beta-galactosidase activity in tissue culture cells. J. Biol. Chem. 277, 20120-20123 (2002).
14. Kisselev, A. & Goldberg, A. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739-758 (2001).
15. Lin, G. et al. Crystal structure of calcium bound domain VI of calpain at 1.9 Å resolution and its role in enzyme assembly, regulation, and inhibitor binding. Nat. Struct. Biol. 4, 539-547 (1997).
16. Welsh, S. & Kay, S. Reporter gene expression for monitoring gene transfer. Curr. Opin. Biotechnol. 8, 617-622 (1997).
17. Dantuma, N., Lindsten, K., Glas, R., Jeline, M. & Masucci, M. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat. Biotechnol. 18, 538-543 (2000).
18. LeBlanc, R. et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000 (2002).
19. Adams, J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med. 8, S49-S54 (2002).
20. Orlowski, R. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427 (2002).
21. Johnson, E., Bartel, B., Seufert, W. & Varshavsky, A. Ubiquitin as a degradation signal. EMBO J. 11, 497-505 (1992).
22. Bence, N., Sampat, R. & Kopito, R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001).